LyGenesis is a technology company.
LyGenesis has raised $22.0M across 2 funding rounds.
LyGenesis has raised $22.0M in total across 2 funding rounds.
LyGenesis has raised $22.0M in total across 2 funding rounds.
LyGenesis's investors include Aisling Capital, Frazier Healthcare Partners, RA Capital.
LyGenesis is a clinical-stage biotechnology company developing allogeneic cell therapies that transform patients' lymph nodes into bioreactors to grow functioning ectopic organs, targeting life-threatening conditions like end-stage liver disease (ESLD), Type 1 diabetes, end-stage renal disease, and aging-related thymus decline.[1][2] It serves patients facing organ failure shortages by offering a less invasive alternative to full organ transplantation—using an outpatient endoscopic ultrasound procedure that reduces medical risks and costs, where one donated organ can treat dozens of patients.[1][2] The company's lead program is in Phase 2A for liver regeneration in ESLD patients, with proof-of-concept (POC) completed for kidney, pancreas, and thymus programs; it reports $10.6 million in revenue and is privately held in Pittsburgh, Pennsylvania.[1][2]
LyGenesis emerged as a spinout from the University of Pittsburgh, leveraging pioneering research in cell therapy for organ regeneration.[3] Key figures include Chief Scientific Officer Eric Lagasse, who drives the science; CEO and Board Member Michael Hufford, highlighted for advancing the technology; and board members like Steve Felstead, Justin Briggs, and James Mellon.[4] The idea stems from discovering lymph nodes' natural ability to act as bioreactors, with early pivotal moments including POC completion across multiple indications and a 2023 joint research collaboration with Imagine Pharma to accelerate Type 1 diabetes therapies.[1][3]
LyGenesis rides the regenerative medicine wave, capitalizing on advances in cell therapy amid a global organ transplant crisis—over 100,000 U.S. waitlist patients yearly, with ESLD alone killing 40,000 annually due to shortages.[2] Timing aligns with biotech's shift to allogeneic therapies post-CAR-T successes, fueled by aging populations driving demand for kidney, liver, and diabetes solutions; market forces like falling gene-editing costs and FDA fast-tracks for orphan diseases amplify this.[1][2] It influences the ecosystem by pioneering "in vivo bioreactors," potentially disrupting $100B+ transplant markets and inspiring spinouts from academic hubs like Pittsburgh.[3]
LyGenesis is poised for milestone readouts in its Phase 2A liver trial, with partnerships like Imagine Pharma accelerating diabetes entry—watch for data in 2026 that could validate scalability and draw big-pharma buyouts.[1] Trends like AI-optimized cell manufacturing and expanded access policies will propel it, evolving its role from Pittsburgh innovator to transplant paradigm-shifter. As organ shortages worsen, LyGenesis's bioreactor model could redefine biotech, turning lymph nodes into factories for life.
LyGenesis has raised $22.0M across 2 funding rounds. Most recently, it raised $19.0M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $19.0M Series A | Aisling Capital, Frazier Healthcare Partners, RA Capital | |
| May 1, 2018 | $3.0M Series A | Aisling Capital, Frazier Healthcare Partners, RA Capital |